莫西沙星等3种氟喹诺酮类药物对95株肺炎链球菌的体外抗菌活性研究

The study on antibacterial activity of moxofloxacin and other 2 fluoroquinolones against 95 strains of Streptococcus pneumoniae

目的:评价莫西沙星、司帕沙星、氧氟沙星等3种氟喹诺酮类药物对95株肺炎链球菌的体外抗菌活 性。方法:根据NCCLs标准,应用微量肉汤稀释法测定3种抗菌药物对95株肺炎链球菌的最低抑菌浓度(MIC)。 结果:在3种氟喹诺酮类药物中,莫西沙星对肺炎链球菌(包括PRSP)抗菌活性最高,MIC90为0.125,肺炎链球菌对 莫西沙星敏感率在95.78%以上。其次是司帕沙星,敏感率在90.53%;氧氟沙星敏感率最低,为82.10%。 结论:莫西沙星对肺炎链球菌有强大的抗菌活性,可作为治疗肺炎链球菌感染的首选药物。

Objective:To evaluate the antibacterial activity of moxofloxacin and other 2 fluoroquinolones against 95 strains of Streptococcus pneumoniae in vitro. Methods:Minimal inhibitory concentrations (MIC) were determined by dilution method according to NCCLs. Results:Moxifloxacin has the best antibacterial activity with the lowest MIC 90, Streptococcus pneumoniae (including Penicillin resistant Streptococcus pneumoniae) showed highest susceptibility to Moxifloxacin with 95.78% susceptible rate, susceptible rate of SIPA and ofloxacin was respectively. Conclusion:moxofloxacin has an powerful antibacterial activity against streptococcus pneumoniae and it can be the first choice to treat streptococcus pneumoniae infection.